RSS

Novartis

Swiss drugmaker Novartis has announced a five-year partnership with the University of Oxford’s Big Data Institute (BDI) to study how artificial intelligence (AI) can provide insights into complex diseases. Read more

News

A collaboration between a Canadian supplier of medical cannabis and a biopharma is being touted as a major step towards bringing medical cannabis to patients across the globe. Read more

News

Healthcare group Novartis will cut 2,000 jobs around the world in response to a changing product portfolio, the company has announced. Read more

News

Novartis’ generics and biosimilars division, Sandoz, has launched the second edition of its Healthcare Access Challenge (Hack), the company has announced. Read more

News

Healthcare solutions provider, Novartis, has announced that the European Commission has approved its combination therapy, Tafinlar + Mekinist, for adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Healthcare solutions provider, Novartis, has announced new data demonstrating that its twice-a-day medicine, Entresto (sacubitril/valsartan) can be initiated early and safely in hospitalised patients after an acute heart failure episode. Read more

News

A brief round up of some of the latest developments in the industry, including a review into medical marijuana and a potential win for Trump in drug pricing… Read more

Opinion

The European Commission (EC) has approved Novartis’ Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraines per month. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

In this case study, a prediction model is used in conjunction with an examination of a tablet profile to resolve sticking issues. Read more

Opinion

The US FDA has accepted Novartis’ supplemental new drug application (sNDA) and granted priority review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of SAA Read more

News

The group general counsel of Swiss pharma company, Novartis, has stepped down from his role, taking personal responsibility for what he has described as the ‘erroneous’ agreement made with Essential Consultants, which is owned by Michael Cohen Read more

News

A treatment for relapsing multiple sclerosis (Gilenya — fingolimod) has been approved for use in children and adolescents aged 10 years and older by the US Food and Drug Administration (FDA). Read more

News

Two drugs, to be administered together for the treatment of ATC that cannot be surgically removed or has spread and has a type of abnormal gene, BRAF V600E, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved by the FDA Read more

News

Swiss-based healthcare company, Novartis, has revealed that the US Food and Drug Administration (FDA) has approved its CAR-T therapy, Kymriah, for its second distinct indication. Read more

News

Swiss-based company, Novartis, has launched a digital research platform created with Apple ResearchKit — FocalView app — which it hopes will modernise ophthalmic clinical trials making them more accessible and flexible. Read more

Technology

Healthcare solutions provider, Novartis, is set to gain further ground in the area of gene therapy through its agreement to acquire AveXis — US-based clinical stage gene therapy company — for $8.7 billion. Read more

News

According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026. Read more

Analysis

Healthcare solutions provider, Novartis, has entered into an agreement with GlaxoSmithKline to divest its 36.5% stake in its consumer healthcare joint venture for $13 billion. Read more

News